Category: Zacks Small Cap Research

1234511830 / 1172 POSTS
By Lisa Thompson OTC:LGIQ READ THE FULL LGIQ RESEARCH REPORT Logiq (OTC:LGIQ) just reported its lowest revenue quarter since it began its business model transition at its AppLogiq division. The good news is, the worst is over and the company expect ...
By John Vandermosten, CFA TSX:HBP.TO | OTC:HBPCF READ THE FULL HBP.TO RESEARCH REPORT Second Quarter Fiscal Year 2021 Operational and Financial Results Helix BioPharma Corp. (TSX:HBP.TO) (OTC:HBPCF) reported 2Q:21 financial and operational results an ...
By John Vandermosten, CFA NASDAQ:RVPH RP5063: Retroactive Comparison Against 32 Antipsychotics An estimated 0.25% to 1% of the global population suffers from schizophrenia. To address this estimated 20 million individuals with the chronic disorder ...
By Lisa Thompson OTC:POETF | TSX:PTK.V READ THE FULL POETF RESEARCH REPORT The only new news in POET’s (OTC:POETF) earnings report was the effect the global foundry capacity shortage is having on the company. First it was a pandemic to deal with and ...
By David Bautz, PhD NASDAQ:SNGX READ THE FULL SNGX RESEARCH REPORT Business Update Rolling NDA Submission for SGX301 to Initiate 2Q21 Soligenix, Inc. (NASDAQ:SNGX) is developing SGX301 for the treatment of cutaneous T cell lymphoma (CTCL). The comp ...
By David Bautz, PhD NASDAQ:BCLI READ THE FULL BCLI RESEARCH REPORT Business Update Positive Proof-of-Concept Data for NurOwn in Progressive MS On March 24, 2021, BrainStorm Cell Therapeutics, Inc. (NASDAQ:BCLI) announced positive proof-of-concept d ...
NASDAQ:TLSA | LSE:TILS Tiziana Life Sciences (NASDAQ:TLSA) (LSE:TILS) disseminated two press releases today updating investors on progress in its Foralumab programs that will address COVID-19 and secondary progressive multiple sclerosis (SPMS). The ...
By M. Marin NASDAQ:ORMP | NASDAQ:VXRT | NASDAQ:ALT READ THE FULL ORMP RESEARCH REPORT Advantages include ease of storage & distribution, plus potential to overcome vaccine hesitancy Oramed Pharmaceuticals Inc. (NASDAQ:ORMP) has announced the for ...
By David Bautz, PhD NASDAQ:DFFN READ THE FULL DFFN RESEARCH REPORT Business Update No Safety Signals for Phase 1b Trial of TSC in COVID-19 Patients On February 16, 2021, Diffusion Pharmaceuticals, Inc. (NASDAQ:DFFN) announced the completion and top ...
By John Vandermosten, CFANASDAQ:LTRN READ THE FULL LTRN RESEARCH REPORT Fourth Quarter and Full Year 2020 Financial and Operational Results On March 10, 2021, Lantern Pharma, Inc. (NASDAQ:LTRN) announced fourth quarter and full year 2020 financial ...
1234511830 / 1172 POSTS